{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:26Z","timestamp":1792784906144,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SIROCO-874146"],"award-info":[{"award-number":["SIROCO-874146"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SparingVision, BPI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rod-cone dystrophies (RCD) are caused by mutations in over 100 genes associated with photoreceptor function, leading to progressive and sequential loss of rod and cone photoreceptors. These mutations generally disrupt retinal metabolism and oxidative stress response accelerating disease progression and vision loss. SPVN06 is an adeno-associated virus (AAV)-based gene- and mutation-agnostic investigational therapy designed to slow cone degeneration by delivering long-term expression of rod-derived cone viability factor (RdCVF) and its full-length isoform, thioredoxin RdCVFL, following a single subretinal administration. These proteins support cone survival by promoting glucose metabolism and reducing oxidative damage, respectively, providing a gene and mutation independent therapeutic approach for RCD. SPVN06 IND-enabling program included pharmacology evaluation in the\n                    <jats:italic>rd10\/rd10<\/jats:italic>\n                    mouse model of RCD (1.0\u2009\u00d7\u200910\n                    <jats:sup>8<\/jats:sup>\n                    vector genomes (vg)\/eye up to 1 month) along with systemic and ocular safety and biodistribution evaluation in non-human primates (NHPs, 6.0\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    to 3.0\u2009\u00d7\u200910\n                    <jats:sup>11<\/jats:sup>\n                    \u2009vg\/eye up to 3 months). In the\n                    <jats:italic>rd10\/rd10<\/jats:italic>\n                    mice, SPVN06 showed preserved vision, as assessed by optokinetic tracking. In NHPs, SPVN06 was well-tolerated up to 6.0\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    \u2009vg\/eye, with high and stable\n                    <jats:italic>RdCVF<\/jats:italic>\n                    and\n                    <jats:italic>RdCVFL<\/jats:italic>\n                    mRNA expression levels in the retina and retinal pigment epithelium. These results supported the initiation of the ongoing Phase I\/II PRODYGY trial with RCD (NCT05748873).\n                  <\/jats:p>","DOI":"10.1038\/s41434-025-00556-3","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:36:02Z","timestamp":1754325362000},"page":"421-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3516-3582","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Marie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Churet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Gautron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Farjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Mizuyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanen","family":"Khabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-8770","authenticated-orcid":false,"given":"Thierry","family":"L\u00e9veillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4831-1153","authenticated-orcid":false,"given":"Jos\u00e9-Alain","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lorget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"556_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","volume":"66","author":"SK Verbakel","year":"2018","unstructured":"Verbakel SK, van Huet RAC, Boon CJF, den Hollander AI, Collin RWJ, Klaver CCW, et al. Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018;66:157\u201386.","journal-title":"Prog Retin Eye Res"},{"key":"556_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.10.002","volume":"62","author":"D Athanasiou","year":"2018","unstructured":"Athanasiou D, Aguila M, Bellingham J, Li W, McCulley C, Reeves PJ, et al. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018;62:1\u201323.","journal-title":"Prog Retin Eye Res"},{"key":"556_CR3","unstructured":"NORD. Retinitis Pigmentosa - NORD Rare Disease Database Danbury CT, USA: National Organization for Rare Disorders (NORD); 2024. https:\/\/rarediseases.org\/rare-diseases\/retinitis-pigmentosa\/."},{"key":"556_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/archopht.125.2.151","volume":"125","author":"SP Daiger","year":"2007","unstructured":"Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Arch Ophthalmol. 2007;125:151\u20138.","journal-title":"Arch Ophthalmol"},{"key":"556_CR5","unstructured":"RetNet. Summaries of Genes and Loci Causing Retinal Diseases 2024 [Available from: https:\/\/retnet.org\/summaries#a-genes."},{"key":"556_CR6","doi-asserted-by":"publisher","first-page":"26ps16","DOI":"10.1126\/scitranslmed.3000866","volume":"2","author":"T Leveillard","year":"2010","unstructured":"Leveillard T, Sahel JA. Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling. Sci Transl Med. 2010;2:26ps16.","journal-title":"Sci Transl Med"},{"key":"556_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/genes12020272","volume":"12","author":"C Turksever","year":"2021","unstructured":"Turksever C, Lopez Torres LT, Valmaggia C, Todorova MG. Retinal oxygenation in inherited diseases of the retina. Genes ((Basel)). 2021;12:272.","journal-title":"Genes ((Basel))"},{"key":"556_CR8","unstructured":"Novartis. Summary of Product Characteristics2024 October 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/luxturna-epar-product-information_en.pdf."},{"key":"556_CR9","unstructured":"Novartis. Summary of Product Characteristics2022 October 2024. Available from: https:\/\/www.fda.gov\/media\/109906\/download."},{"key":"556_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1068185","volume":"15","author":"MC John","year":"2022","unstructured":"John MC, Quinn J, Hu ML, Cehajic-Kapetanovic J, Xue K. Gene-agnostic therapeutic approaches for inherited retinal degenerations. Front Mol Neurosci. 2022;15:1068185.","journal-title":"Front Mol Neurosci"},{"key":"556_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40123-023-00862-2","volume":"13","author":"AS Brar","year":"2024","unstructured":"Brar AS, Parameswarappa DC, Takkar B, Narayanan R, Jalali S, Mandal S, et al. Gene Therapy for Inherited Retinal Diseases: From Laboratory Bench to Patient Bedside and Beyond. Ophthalmol Ther. 2024;13:21\u201350.","journal-title":"Ophthalmol Ther"},{"key":"556_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-319-75402-4_10","volume":"1074","author":"C Fortuny","year":"2018","unstructured":"Fortuny C, Flannery JG. Mutation-independent gene therapies for rod-cone dystrophies. Adv Exp Med Biol. 2018;1074:75\u201381.","journal-title":"Adv Exp Med Biol"},{"key":"556_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ng1386","volume":"36","author":"T Leveillard","year":"2004","unstructured":"Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, et al. Identification and characterization of rod-derived cone viability factor. Nat Genet. 2004;36:755\u20139.","journal-title":"Nat Genet"},{"key":"556_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1172\/JCI65654","volume":"125","author":"LC Byrne","year":"2015","unstructured":"Byrne LC, Dalkara D, Luna G, Fisher SK, Clerin E, Sahel JA, et al. Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J Clin Invest. 2015;125:105\u201316.","journal-title":"J Clin Invest"},{"key":"556_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cell.2015.03.023","volume":"161","author":"N Ait-Ali","year":"2015","unstructured":"Ait-Ali N, Fridlich R, Millet-Puel G, Clerin E, Delalande F, Jaillard C, et al. Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell. 2015;161:817\u201332.","journal-title":"Cell"},{"key":"556_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1089\/ars.2015.6509","volume":"24","author":"Mei","year":"2016","unstructured":"Mei, Chaffiol A X, Kole C, Yang Y, Millet-Puel G, Clerin E, et al. The thioredoxin encoded by the rod-derived cone viability factor gene protects cone photoreceptors against oxidative stress. Antioxid Redox Signal. 2016;24:909\u201323.","journal-title":"Antioxid Redox Signal"},{"key":"556_CR17","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.celrep.2018.04.111","volume":"23","author":"L Petit","year":"2018","unstructured":"Petit L, Ma S, Cipi J, Cheng SY, Zieger M, Hay N, et al. Aerobic glycolysis is essential for normal rod function and controls secondary cone death in retinitis pigmentosa. Cell Rep. 2018;23:2629\u201342.","journal-title":"Cell Rep"},{"key":"556_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.freeradbiomed.2015.01.003","volume":"81","author":"G Elachouri","year":"2015","unstructured":"Elachouri G, Lee-Rivera I, Clerin E, Argentini M, Fridlich R, Blond F, et al. Thioredoxin rod-derived cone viability factor protects against photooxidative retinal damage. Free Radic Biol Med. 2015;81:22\u20139.","journal-title":"Free Radic Biol Med"},{"key":"556_CR19","unstructured":"SparingVision Announces Favorable Safety Update from PRODYGY Trial at ARVO 2025 2025 [Available from: https:\/\/sparingvision.com\/sparingvision-announces-favorable-safety-update-from-prodygy-trial-at-arvo-2025\/."},{"key":"556_CR20","unstructured":"SparingVision Announces Presentation of SPVN06 Safety Data at the Macula Society 48th Annual Meeting 2025 [Available from: https:\/\/sparingvision.com\/presentation-of-spvn06-safety-data-at-the-macula-society-48th-annual-meeting\/."},{"key":"556_CR21","first-page":"A0029","volume":"63","author":"F Lorget","year":"2022","unstructured":"Lorget F, Marie M, Khabou H, Simon C, Nuno D, Vanlandingham P, et al. SPVN06, a novel mutation-independent AAV-based gene therapy, dramatically reduces vision loss in the rd10 mouse model of rod-cone dystrophy. Invest Ophthalmol Vis Sci. 2022;63:A0029.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"556_CR22","first-page":"2591","volume":"64","author":"M Marie","year":"2023","unstructured":"Marie M, Churet L, Khabou H, Chung DC, Sahel J, L\u00e9veillard T, et al. Mouse model selection for pharmacological evaluation of AAV-based therapeutic agents for the treatment of Rod-Cone Dystrophies (RCD). Invest Ophthalmol Vis Sci. 2023;64:2591.\u00a0https:\/\/sparingvision.com\/wp-content\/uploads\/2023\/05\/2023-SPVN_ARVO_2023_MM.pdf.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"556_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0042-6989(01)00146-8","volume":"42","author":"B Chang","year":"2002","unstructured":"Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR. Retinal degeneration mutants in the mouse. Vision Res. 2002;42:517\u201325.","journal-title":"Vision Res"},{"key":"556_CR24","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1128\/MCB.00181-15","volume":"35","author":"M Du","year":"2015","unstructured":"Du M, Otalora L, Martin AA, Moiseyev G, Vanlandingham P, Wang Q, et al. Transgenic mice overexpressing serum retinol-binding protein develop progressive retinal degeneration through a retinoid-independent mechanism. Mol Cell Biol. 2015;35:2771\u201389.","journal-title":"Mol Cell Biol"},{"key":"556_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1089\/jop.2017.0108","volume":"33","author":"JS Eaton","year":"2017","unstructured":"Eaton JS, Miller PE, Bentley E, Thomasy SM, Murphy CJ. The SPOTS System: An Ocular Scoring System Optimized for Use in Modern Preclinical Drug Development and Toxicology. J Ocul Pharmacol Ther. 2017;33:718\u201334.","journal-title":"J Ocul Pharmacol Ther"},{"key":"556_CR26","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.1167\/iovs.17-22473","volume":"58","author":"IP Seitz","year":"2017","unstructured":"Seitz IP, Michalakis S, Wilhelm B, Reichel FF, Ochakovski GA, Zrenner E, et al. Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates. Invest Ophthalmol Vis Sci. 2017;58:5792\u2013801.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"556_CR27","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the non-clinical studies required before first clinical use of gene therapy medicinal products2008 December 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-non-clinical-studies-required-first-clinical-use-gene-therapy-medicinal-products_en.pdf."},{"key":"556_CR28","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Nonclinical biodistribution considerations for gene therapy products S122023 December 2024. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_S12_Step4_Guideline_2023_0314.pdf."},{"key":"556_CR29","unstructured":"Committee for Advanced Therapies (CAT). Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products2018 December 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products_en.pdf."},{"key":"556_CR30","first-page":"2579","volume":"19","author":"J Han","year":"2013","unstructured":"Han J, Dinculescu A, Dai X, Du W, Smith WC, Pang J. Review: the history and role of naturally occurring mouse models with Pde6b mutations. Mol Vis. 2013;19:2579\u201389.","journal-title":"Mol Vis"},{"key":"556_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cne.21144","volume":"500","author":"C Gargini","year":"2007","unstructured":"Gargini C, Terzibasi E, Mazzoni F, Strettoi E. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG study. J Comp Neurol. 2007;500:222\u201338.","journal-title":"J Comp Neurol"},{"key":"556_CR32","first-page":"1189","volume":"62","author":"J Noel","year":"2021","unstructured":"Noel J, Jalligampala A, Marussig M, Vinot PA, Marie M, Butler M, et al. SPVN06, a novel mutation-independent AAV-based gene therapy, protects cone degeneration in a pig model of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2021;62:1189.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"556_CR33","doi-asserted-by":"publisher","first-page":"26280","DOI":"10.1073\/pnas.1902292116","volume":"116","author":"S Picaud","year":"2019","unstructured":"Picaud S, Dalkara D, Marazova K, Goureau O, Roska B, Sahel JA. The primate model for understanding and restoring vision. Proc Natl Acad Sci USA. 2019;116:26280\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"556_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2023.108258","volume":"210","author":"A Shamshad","year":"2023","unstructured":"Shamshad A, Kang C, Jenny LA, Persad-Paisley EM, Tsang SH. Translatability barriers between preclinical and clinical trials of AAV gene therapy in inherited retinal diseases. Vision Res. 2023;210:108258.","journal-title":"Vision Res"},{"key":"556_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.joco.2018.01.006","volume":"30","author":"H Ameri","year":"2018","unstructured":"Ameri H. Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. J Curr Ophthalmol. 2018;30:1\u20132.","journal-title":"J Curr Ophthalmol"},{"key":"556_CR36","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849\u201360.","journal-title":"Lancet"},{"key":"556_CR37","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.3390\/jcm11164717","volume":"11","author":"C Irigoyen","year":"2022","unstructured":"Irigoyen C, Amenabar Alonso A, Sanchez-Molina J, Rodriguez-Hidalgo M, Lara-Lopez A, Ruiz-Ederra J. Subretinal injection techniques for retinal disease: a review. J Clin Med. 2022;11:4717.","journal-title":"J Clin Med"},{"key":"556_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.omtm.2023.02.002","volume":"28","author":"R Ferla","year":"2023","unstructured":"Ferla R, Dell\u2019Aquila F, Doria M, Ferraiuolo M, Noto A, Grazioli F, et al. Efficacy, pharmacokinetics, and safety in the mouse and primate retina of dual AAV vectors for Usher syndrome type 1B. Mol Ther Methods Clin Dev. 2023;28:396\u2013411.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"556_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2017.12.001","volume":"8","author":"TK MacLachlan","year":"2018","unstructured":"MacLachlan TK, Milton MN, Turner O, Tukov F, Choi VW, Penraat J, et al. Nonclinical safety evaluation of scAAV8-RLBP1 for treatment of RLBP1 retinitis pigmentosa. Mol Ther Methods Clin Dev. 2018;8:105\u201320.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"556_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","volume":"138","author":"MD Fischer","year":"2020","unstructured":"Fischer MD, Michalakis S, Wilhelm B, Zobor D, Muehlfriedel R, Kohl S, et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial. JAMA Ophthalmol. 2020;138:643\u201351.","journal-title":"JAMA Ophthalmol"},{"key":"556_CR41","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","volume":"25","author":"FF Reichel","year":"2017","unstructured":"Reichel FF, Dauletbekov DL, Klein R, Peters T, Ochakovski GA, Seitz IP, et al. AAV8 can induce innate and adaptive immune response in the primate eye. Mol Ther. 2017;25:2648\u201360.","journal-title":"Mol Ther"},{"key":"556_CR42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","volume":"24","author":"D Ail","year":"2022","unstructured":"Ail D, Ren D, Brazhnikova E, Nouvel-Jaillard C, Bertin S, Mirashrafi SB, et al. Systemic and local immune responses to intraocular AAV vector administration in non-human primates. Mol Ther Methods Clin Dev. 2022;24:306\u201316.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"556_CR43","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/pnas.1821000116","volume":"116","author":"W Xiong","year":"2019","unstructured":"Xiong W, Wu DM, Xue Y, Wang SK, Chung MJ, Ji X, et al. AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA. 2019;116:5785\u201394.","journal-title":"Proc Natl Acad Sci USA"},{"key":"556_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1242\/dmm.003772","volume":"3","author":"Y Alvarez","year":"2010","unstructured":"Alvarez Y, Chen K, Reynolds AL, Waghorne N, O\u2019Connor JJ, Kennedy BN. Predominant cone photoreceptor dysfunction in a hyperglycaemic model of non-proliferative diabetic retinopathy. Dis Model Mech. 2010;3:236\u201345.","journal-title":"Dis Model Mech"},{"key":"556_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1152\/physrev.00010.2014","volume":"96","author":"XG Lei","year":"2016","unstructured":"Lei XG, Zhu JH, Cheng WH, Bao Y, Ho YS, Reddi AR, et al. Paradoxical roles of antioxidant enzymes: basic mechanisms and health implications. Physiol Rev. 2016;96:307\u201364.","journal-title":"Physiol Rev"},{"key":"556_CR46","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/mt.2010.273","volume":"19","author":"JJ Pang","year":"2011","unstructured":"Pang JJ, Dai X, Boye SE, Barone I, Boye SL, Mao S, et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther. 2011;19:234\u201342.","journal-title":"Mol Ther"},{"key":"556_CR47","doi-asserted-by":"publisher","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","volume":"3","author":"LH Vandenberghe","year":"2011","unstructured":"Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R, et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med. 2011;3:88ra54.","journal-title":"Sci Transl Med"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00556-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:57:07Z","timestamp":1786607827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00556-3","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM, LC, ASG, HK, FL are employees of SparingVision. RF is an employee of EyeCRO. KM is an employee of SNBL. VS is an employee of Charles River Laboratories. TL received research support from SparingVision and was a consultant for SparingVision. JAS and TL are cofounders of SparingVision. TL and JAS are shareholders of SparingVision related to PCT applications PCT\/EP2016\/061488 and PCT\/EP2018\/086744. MM, ASG, HK, TL, JAS, FL have personal financial interest in SparingVision.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All experiments were performed in accordance with relevant guidelines and regulations. Studies in\n                      rd10\/rd10\n                      mice were conducted at the EyeCRO animal facility (accredited by the American Association for Accreditation of Laboratory Animal Care [AAALAC] International). All experimental procedures adhered to the Association for Research in Vision and Ophthalmology [ARVO] Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the EyeCRO Institutional Animal Care and Use Committee (approval number SOW003 IACUC #2019-01-17-002). Data from a separate study conducted at the same facility in na\u00efve wild-type (WT) mice were included to serve as an additional reference point (approval number SOW001 IACUC #2019-01-17-002). Three studies were conducted in NHPs: one 4-week pilot study, and two 13-week Good Laboratory Practice (GLP) studies: a high-dose study and a low-dose study, each involving multiple doses. All three studies were conducted with cynomolgus macaques (\n                      Macaca fascicularis\n                      ). The 4-week pilot study and GLP high-dose study were conducted at the Charles River Laboratories in Mattawan, USA (CR-MWN), where protocols were reviewed and approved by the CR-MWN Institutional Animal Care and Use Committee (IACUC, ethical body) in accordance with the guidelines of the US National Research Council (approval numbers: 3228-001 for the pilot study and 3228-002 for the GLP high-dose study). A second GLP study using lower doses of SPVN06 (GLP low-dose study) was conducted subsequently at Shin Nippon Biomedical Laboratories, Ltd (SNBL) in Kagoshima, Japan. The protocol for this study was reviewed and approved by SNBL IACUC (approval number IACUC563-001) and Recombinant Gene Experiment Safety Committee (approval number LMOD-563001), and was conducted in compliance with the animal welfare regulations of SNBL, which is accredited by AAALAC International.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}